	US 11,897,964 B2
	Anti-PSGL-1 antibodies and uses thereof
Stefan Bassarab, Biberach an der Riss (DE); Barbara Enenkel, Warthausen (DE); Patrick Garidel, Norderstedt (DE); Heidrun Schott, Schemmerhofen (DE); Sanjaya Singh, Sandy Hook, CT (US); and Tobias Litzenburger, Mittelbiberach (DE)
Assigned to AltruBio Inc., Wilmington, DE (US)
Filed by AltruBio Inc., Wilmington, DE (US)
Filed on Aug. 30, 2021, as Appl. No. 17/460,883.
Application 17/460,883 is a division of application No. 13/494,398, filed on Jun. 12, 2012, abandoned.
Claims priority of provisional application 61/496,249, filed on Jun. 13, 2011.
Prior Publication US 2021/0395383 A1, Dec. 23, 2021
Int. Cl. C07K 16/28 (2006.01); A61K 39/00 (2006.01)

CPC C07K 16/2896 (2013.01) [A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/53 (2013.01)]

5 Claims

1. A method for treating graft-versus-host disease (GVHD), psoriatic arthritis, or ulcerative colitis, the method comprising injecting into to a human subject in need thereof a pharmaceutical composition comprising:

(i) a monoclonal antibody which immunospecifically binds to human PSGL-1 comprising:

(a) a light chain comprising a variable light (“VL”) chain region comprising the amino acid sequence of SEQ ID NO: 3;

(b) a heavy chain comprising variable heavy (“VH”) chain region comprising the amino acid sequence of SEQ ID NO: 4; and

(c) a human IgG4 constant region which contains a Serine to Proline substitution at amino acid 228 of the heavy chain numbered according to the EU index; and

(ii) a pharmaceutically acceptable carrier,

wherein, the pharmaceutical composition comprises less than 1% half antibody molecules, wherein upon administration to the subject, the pharmaceutical composition inhibits T-cell mediated inflammation in the subject, and wherein the monoclonal antibody of the pharmaceutical composition administered to the subject is present at a concentration between 0.03 mg/kg and 10 mg/kg.